Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
938-73-8
Molecular formula
C9H11NO2
Molecular weight
165.19 g/mol
Drug class
Salicylamide-derived non-steroidal analgesic and antipyretic
Mechanism of action
The precise mechanism is not completely established. Ethenzamide has analgesic and antipyretic activity; experimental studies suggest spinal and central actions, including antagonism at 5-HT2B receptors. Unlike classical salicylates, it has shown little or no direct inhibition of COX-1 or COX-2 in some studies.
Indications / reported uses
Used as an analgesic and antipyretic, commonly in combination products, in countries where ethenzamide is authorised.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Ethenzamide PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Ethenzamide Permitted Daily Exposure (PDE) report (the Ethenzamide PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Ethenzamide Occupational Exposure Limit (OEL) report (the Ethenzamide OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.